AstraZeneca Results Presentation Deck
FY 2020: total revenue +10%
New medicines continued to grow
8
Total revenue growth, per cent
FY 2015
Changes at CER.
FY 2016
Significant revenue recovery including
an anticipated Lynparza sales milestone
FY 2017
Q1 2018
Q2 2018
Q3 2018
14%
Q4 2018
11%
Q1 2019
18%
Q2 2019
22%
Q3 2019
5%
Q4 2019
17%
Q1 2020
11%
Q2 2020
3%
10%
Q3 2020
Q4 2020
Bevespi
7470
Breztri
roxadustat
New medicines the
major contributor
Brilinta
+$3.5bn
incremental revenue of the new
medicines compared to FY 2019¹
Lokelm
Koselugo
Enhertu
Fasenra
Lynparza
Calquence
Farxiga
Imfinzi
Tagrisso
Oncology New CVRM Respiratory & Immunology
Absolute values at CER. 1. Total revenue for Tagrisso, Imfinzi, Farxiga, Lynparza, Calquence, Fasenra, Enhertu, Lokelma,
Koselugo, Brilinta, roxadustat, Breztri and Bevespi.
$m
1,200
1,000
800
600
400
-200
4View entire presentation